XSHE
003020
Market cap477mUSD
Jul 10, Last price
18.74CNY
1D
9.98%
1Q
-7.37%
IPO
-13.56%
Name
Hefei Lifeon Pharmaceutical Co Ltd
Chart & Performance
P/E
21.57
P/S
2.29
EPS
0.87
Div Yield, %
4.11%
Shrs. gr., 5y
0.21%
Rev. gr., 5y
-7.33%
Revenues
1.55b
+2.33%
Net income
165m
+2.86%
CFO
213m
+7.77%
Dividend
Nov 28, 20250.2 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Hefei Lifeon Pharmaceutical Co., Ltd. specializes in the research, development, production, and distribution of a wide array of pharmaceutical goods. Its product portfolio encompasses active pharmaceutical ingredients (APIs) such as succimer, urea, paeonol, felodipine, doxazosin mesylate, zofenopril calcium, troxerutin, and sodium 2,3-dimercapto-1-propanesulfonate. The company also manufactures various medicinal preparations, including felodipine sustained-release tablets, doxazosin mesylate extended-release tablets, melbinum glipizide tablets, yiqihewei capsules, kunning granules, armillariella oral solution, paeonol ointment, urea and vitamin E cream, Kecuo Yintong gel, and Compound Golden Larch bark gel. Additionally, Hefei Lifeon Pharmaceutical supplies plant extracts like clove oil, evening primrose oil, herba clinopodii P.E, quercetin, and dihydroquercetin. Beyond its manufacturing operations, the company operates a retail chain for pharmaceuticals. Established in 2002, Hefei Lifeon Pharmaceutical Co., Ltd. is headquartered in Hefei, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||||
Revenues | |||||||||||
Cost of revenue | |||||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | |||||||||||
NOPBT Margin | |||||||||||
Operating Taxes | |||||||||||
Tax Rate | |||||||||||
NOPAT | |||||||||||
Net income | |||||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | |||||||||||
BB yield | |||||||||||
| Debt | |||||||||||
Debt current | |||||||||||
Long-term debt | |||||||||||
Deferred revenue | |||||||||||
Other long-term liabilities | |||||||||||
Net debt | |||||||||||
| Cash flow | |||||||||||
Cash from operating activities | |||||||||||
CAPEX | |||||||||||
Cash from investing activities | |||||||||||
Cash from financing activities | |||||||||||
FCF | |||||||||||
| Balance | |||||||||||
Cash | |||||||||||
Long term investments | |||||||||||
Excess cash | |||||||||||
Stockholders' equity | |||||||||||
Invested Capital | |||||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | |||||||||||
Price | |||||||||||
Market cap | |||||||||||
EV | |||||||||||
EBITDA | |||||||||||
EV/EBITDA | |||||||||||
Interest | |||||||||||
Interest/NOPBT | |||||||||||